drugset / Trial / NCT04622891

Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection

NCT04622891

Completed 300 enrolled South Valley University
RandomizedParallel-groupDouble-blindTreatment

Summary

The current study was conducted at Qena Governorate, Egypt, during the period from May 2020, to July 2020. The study included 305 COVID-19 cases diagnosed by PCR, patients were randomly assigned to one of three study limps, Azithromycin 500 mg/24 h for 7 days, Clarithromycin 500 /12 h for 7 days, or a control group with no antibiotics, All three groups received only symptomatic treatment for control of fever and cough

Timeline

Start
2020-04-01
Primary completion
2020-07-30
Completion
2020-07-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azithromycin Small molecule 500 mg
Subject Clarithromycin Small molecule 500 mg

Indications